Difficult‐to‐treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment
United European Gastroenterology Journal · 2024
DOI: 10.1002/ueg2.12547 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Bénédicte Caron und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Ustekinumab, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Many patients with inflammatory bowel disease (IBD) have signs or symptoms of active disease despite multiple treatment attempts. This emerging concept is defined as difficult‐to‐treat IBD.
Aim
The objective of this study was to investigate for the first time the treatment persistence, efficacy and safety of biologics or small molecules used in 4th or 5th line therapy.
Methods
We reviewed all consecutive patients with IBD treated at the Nancy University Hospital between July 2022 and April 2023 with the 4th or 5th line treatment for at least three months. The primary outcome was to assess the persistence rate of 4th and 5th line therapy.
Results
We enrolled 82 patients with IBD (4th line: 44; 5th line: 38). On Kaplan–Meier analysis, the duration of risankizumab, ustekinumab or vedolizumab therapy did not differ significantly ( p > 0.05) as 4th and 5th line treatment. The restricted mean survival time analysis showed that the persistence rate of risankizumab was the highest as 4th line therapy (risankizumab vs. vedolizumab: 36.0 and 29.4 weeks, respectively, p = 0.008; risankizumab vs. ustekinumab: 36.0 and 32.8 weeks, respectively, p = 0.035). In multivariate regression, Crohn's disease diagnosis (Odd ratio 4.6; 95% confidence interval 1.7–12.4) was significantly associated with treatment persistence.
Conclusion
In this first real‐world setting, risankizumab could have a longer persistence rate as 4th line treatment for IBD than other agents. Persistence of biological agents was greater in Crohn's disease than in ulcerative colitis. More studies are needed to compare treatment efficacy in patients with difficult‐to‐treat IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
- INSERM, NGERE, University of Lorraine, Nancy, France.
- INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
- FHU-CURE, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
- Unit of Methodology, Data Management and Statistic, Nancy University Hospital, Vandoeuvre-lès-Nancy, France.
- Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy.
ORCID-Profile: Tommaso Lorenzo Parigi, Silvio Danese, Laurent Peyrin-Biroulet
Zitieren
APA
Caron, B., Habert, A., Bonsack, O., Camara, H., Jeanbert, E., Parigi, T. L., Netter, P., Danese, S., & Peyrin-Biroulet, L. (2024). Difficult‐to‐treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12547
Vancouver
Caron B, Habert A, Bonsack O, Camara H, Jeanbert E, Parigi TL, et al. Difficult‐to‐treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12547
BibTeX
@article{Caron2024,
author = {Caron, Bénédicte and Habert, Alexandre and Bonsack, Olivier and Camara, Houda and Jeanbert, Elodie and Parigi, Tommaso Lorenzo and Netter, Patrick and Danese, Silvio and Peyrin-Biroulet, Laurent},
title = {Difficult‐to‐treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment},
journal = {United European Gastroenterology Journal},
year = {2024},
doi = {10.1002/ueg2.12547}
}
EUVIMED